Rhenman & Partners Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,778	Closed	-$272K	–	101
2019 Q3	$272K	Hold	10,778	–	–	0.03%	86
2019 Q2	$274K	Hold	10,778	–	–	0.03%	84
2019 Q1	$458K	Hold	10,778	–	–	0.05%	79
2018 Q4	$157K	Sell	10,778 -1,440	-12%	-$58.8K	0.02%	89
2018 Q3	$855K	Hold	12,218	–	–	0.09%	72
2018 Q2	$907K	Sell	12,218 -642	-5%	-$57.2K	0.09%	72
2018 Q1	$1.22M	Hold	12,860	–	–	0.15%	73
2017 Q4	$1.66M	Buy	+12,860	New	+$1.21M	0.22%	74
2014 Q4	–	Sell	-958	Closed	-$1.44M	–	95
2014 Q3	$1.44M	Hold	958	–	–	0.42%	87
2014 Q2	$1.31M	Buy	958 +256	+36%	+$297K	0.39%	78
2014 Q1	$974K	Buy	+702	New	+$816K	0.29%	81

Other funds holding VIRX

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Rhenman & Partners Asset Management's VIRX Position: Q4 2019 in Review

Rhenman & Partners Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2019, closing a stake of 10,778 shares — an estimated $272K sold.

Rhenman & Partners Asset Management first reported a position in VIRX in Q1 2014 and held it in 11 quarters. The position peaked at $1.66M in Q4 2017. 44 funds tracked by Wall St. Rank hold VIRX as of Q4 2019.

Rhenman & Partners Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Rhenman & Partners Asset Management sold 10,778 Viracta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $272K.
Rhenman & Partners Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 11 quarters.
Rhenman & Partners Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $1.66M in Q4 2017.
44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.